Defining the PKD Dosage Threshold: Mechanistic Drivers & Therapeutic Strategies to Elevate PC1 in ADPKD
- Dissecting the two‑hit model and how sub‑threshold PC1 levels initiate cystogenesis
- Characterizing PKD1/PKD2 dosage requirements that modulate disease penetrance and progression
- Reviewing emerging therapeutic approaches designed to increase functional PC1 and restore cellular homeostasis
- Integrating mechanistic insights with translational efforts to accelerate dose‑targeted ADPKD therapies